Amylyx Pharmaceuticals (AMLX) Gross Margin (2022 - 2024)

Amylyx Pharmaceuticals' Gross Margin history runs 3 years deep, the most recent figure standing at 100.0% for Q4 2024.

• In Q4 2024, Gross Margin rose 1232.0% year-over-year to 100.0%; the TTM figure through Sep 2025 stood at 100.0% (up 922.0% YoY), while the FY2024 annual figure was 93.19%, down 13.0% from the prior year.
• Gross Margin was 100.0% for Q4 2024 at Amylyx Pharmaceuticals, roughly flat from 100.0% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 100.0% in Q3 2024 to a low of 68.56% in Q3 2022.
• Historically, Gross Margin has averaged 91.93% across 3 years, with a median of 94.3% in 2023.
• The sharpest annual moves came in 2023 and 2024: Gross Margin soared 2636 bps in 2023, then plunged 46 bps in 2024.
• A 3-year view of Gross Margin shows it stood at 86.99% in 2022, then gained by 1 bps to 87.68% in 2023, then increased by 14 bps to 100.0% in 2024.
• The last three Gross Margin figures came in at 100.0% (Q4 2024), 100.0% (Q3 2024), and 99.22% (Q2 2024), per Business Quant data.